FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043358081> ?p ?o ?g. }

• W2043358081 endingPage "620" @default.
• W2043358081 startingPage "614" @default.
• W2043358081 abstract "Purpose To identify , within the framework of a current Phase I trial, whether factors related to intraprostatic cancer lesions (IPLs) or individual patients predict the feasibility of high-dose intraprostatic irradiation. Methods and Materials Endorectal coil MRI scans of the prostate from 42 men were evaluated for dominant IPLs. The IPLs, prostate, and critical normal tissues were contoured. Intensity-modulated radiotherapy plans were generated with the goal of delivering 75.6 Gy in 1.8-Gy fractions to the prostate, with IPLs receiving a simultaneous integrated boost of 3.6 Gy per fraction to a total dose of 151.2 Gy, 200% of the prescribed dose and the highest dose cohort in our trial. Rectal and bladder dose constraints were consistent with those outlined in current Radiation Therapy Oncology Group protocols. Results Dominant IPLs were identified in 24 patients (57.1%). Simultaneous integrated boosts (SIB) to 200% of the prescribed dose were achieved in 12 of the 24 patients without violating dose constraints. Both the distance between the IPL and rectum and the hip-to-hip patient width on planning CT scans were associated with the feasibility to plan an SIB (p = 0.002 and p = 0.0137, respectively). Conclusions On the basis of this small cohort, the distance between an intraprostatic lesion and the rectum most strongly predicted the ability to plan high-dose radiation to a dominant intraprostatic lesion. High-dose SIB planning seems possible for select intraprostatic lesions. To identify , within the framework of a current Phase I trial, whether factors related to intraprostatic cancer lesions (IPLs) or individual patients predict the feasibility of high-dose intraprostatic irradiation. Endorectal coil MRI scans of the prostate from 42 men were evaluated for dominant IPLs. The IPLs, prostate, and critical normal tissues were contoured. Intensity-modulated radiotherapy plans were generated with the goal of delivering 75.6 Gy in 1.8-Gy fractions to the prostate, with IPLs receiving a simultaneous integrated boost of 3.6 Gy per fraction to a total dose of 151.2 Gy, 200% of the prescribed dose and the highest dose cohort in our trial. Rectal and bladder dose constraints were consistent with those outlined in current Radiation Therapy Oncology Group protocols. Dominant IPLs were identified in 24 patients (57.1%). Simultaneous integrated boosts (SIB) to 200% of the prescribed dose were achieved in 12 of the 24 patients without violating dose constraints. Both the distance between the IPL and rectum and the hip-to-hip patient width on planning CT scans were associated with the feasibility to plan an SIB (p = 0.002 and p = 0.0137, respectively). On the basis of this small cohort, the distance between an intraprostatic lesion and the rectum most strongly predicted the ability to plan high-dose radiation to a dominant intraprostatic lesion. High-dose SIB planning seems possible for select intraprostatic lesions." @default.
• W2043358081 created "2016-06-24" @default.
• W2043358081 creator A5001021073 @default.
• W2043358081 creator A5003804288 @default.
• W2043358081 creator A5036663495 @default.
• W2043358081 creator A5058195225 @default.
• W2043358081 creator A5063104560 @default.
• W2043358081 creator A5067320445 @default.
• W2043358081 creator A5076213753 @default.
• W2043358081 creator A5082080836 @default.
• W2043358081 creator A5083432144 @default.
• W2043358081 date "2011-06-01" @default.
• W2043358081 modified "2023-10-16" @default.
• W2043358081 title "Parameters Favorable to Intraprostatic Radiation Dose Escalation in Men With Localized Prostate Cancer" @default.
• W2043358081 cites W1602790399 @default.
• W2043358081 cites W1608442576 @default.
• W2043358081 cites W1963622760 @default.
• W2043358081 cites W1964244332 @default.
• W2043358081 cites W1966835220 @default.
• W2043358081 cites W1976784469 @default.
• W2043358081 cites W1984897338 @default.
• W2043358081 cites W1987395492 @default.
• W2043358081 cites W1988691059 @default.
• W2043358081 cites W1994364707 @default.
• W2043358081 cites W1996809772 @default.
• W2043358081 cites W1999045406 @default.
• W2043358081 cites W2003634131 @default.
• W2043358081 cites W2004080729 @default.
• W2043358081 cites W2016557692 @default.
• W2043358081 cites W2017834862 @default.
• W2043358081 cites W2056643793 @default.
• W2043358081 cites W2058060929 @default.
• W2043358081 cites W2067125737 @default.
• W2043358081 cites W2073291129 @default.
• W2043358081 cites W2081292833 @default.
• W2043358081 cites W2084016197 @default.
• W2043358081 cites W2085845883 @default.
• W2043358081 cites W2089918768 @default.
• W2043358081 cites W2093059233 @default.
• W2043358081 cites W2103429819 @default.
• W2043358081 cites W2117933226 @default.
• W2043358081 cites W2133094593 @default.
• W2043358081 cites W2140307920 @default.
• W2043358081 cites W2146822966 @default.
• W2043358081 cites W2149278436 @default.
• W2043358081 cites W2156261634 @default.
• W2043358081 cites W2156608244 @default.
• W2043358081 cites W2161070145 @default.
• W2043358081 cites W2165724159 @default.
• W2043358081 cites W2167818099 @default.
• W2043358081 doi "https://doi.org/10.1016/j.ijrobp.2010.06.050" @default.
• W2043358081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3580994" @default.
• W2043358081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20932672" @default.
• W2043358081 hasPublicationYear "2011" @default.
• W2043358081 type Work @default.
• W2043358081 sameAs 2043358081 @default.
• W2043358081 citedByCount "34" @default.
• W2043358081 countsByYear W20433580812012 @default.
• W2043358081 countsByYear W20433580812013 @default.
• W2043358081 countsByYear W20433580812014 @default.
• W2043358081 countsByYear W20433580812015 @default.
• W2043358081 countsByYear W20433580812016 @default.
• W2043358081 countsByYear W20433580812017 @default.
• W2043358081 countsByYear W20433580812018 @default.
• W2043358081 countsByYear W20433580812020 @default.
• W2043358081 countsByYear W20433580812021 @default.
• W2043358081 countsByYear W20433580812022 @default.
• W2043358081 countsByYear W20433580812023 @default.
• W2043358081 crossrefType "journal-article" @default.
• W2043358081 hasAuthorship W2043358081A5001021073 @default.
• W2043358081 hasAuthorship W2043358081A5003804288 @default.
• W2043358081 hasAuthorship W2043358081A5036663495 @default.
• W2043358081 hasAuthorship W2043358081A5058195225 @default.
• W2043358081 hasAuthorship W2043358081A5063104560 @default.
• W2043358081 hasAuthorship W2043358081A5067320445 @default.
• W2043358081 hasAuthorship W2043358081A5076213753 @default.
• W2043358081 hasAuthorship W2043358081A5082080836 @default.
• W2043358081 hasAuthorship W2043358081A5083432144 @default.
• W2043358081 hasBestOaLocation W20433580812 @default.
• W2043358081 hasConcept C121608353 @default.
• W2043358081 hasConcept C126322002 @default.
• W2043358081 hasConcept C126838900 @default.
• W2043358081 hasConcept C126894567 @default.
• W2043358081 hasConcept C141071460 @default.
• W2043358081 hasConcept C201645570 @default.
• W2043358081 hasConcept C2776235491 @default.
• W2043358081 hasConcept C2780192828 @default.
• W2043358081 hasConcept C2781074409 @default.
• W2043358081 hasConcept C2781156865 @default.
• W2043358081 hasConcept C2989005 @default.
• W2043358081 hasConcept C509974204 @default.
• W2043358081 hasConcept C71924100 @default.
• W2043358081 hasConcept C72563966 @default.
• W2043358081 hasConceptScore W2043358081C121608353 @default.
• W2043358081 hasConceptScore W2043358081C126322002 @default.
• W2043358081 hasConceptScore W2043358081C126838900 @default.
• W2043358081 hasConceptScore W2043358081C126894567 @default.
• W2043358081 hasConceptScore W2043358081C141071460 @default.

• next